Baker BROS. Advisors LP Has $16.24 Million Stake in Contineum Therapeutics, Inc. $CTNM

Baker BROS. Advisors LP lifted its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 1,729.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,420,838 shares of the company’s stock after buying an additional 1,343,168 shares during the period. Baker BROS. Advisors LP’s holdings in Contineum Therapeutics were worth $16,240,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of CTNM. Strs Ohio acquired a new position in shares of Contineum Therapeutics during the first quarter worth approximately $27,000. Qube Research & Technologies Ltd acquired a new position in shares of Contineum Therapeutics during the second quarter worth approximately $43,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Contineum Therapeutics during the fourth quarter worth approximately $43,000. Marex Group plc acquired a new position in shares of Contineum Therapeutics during the second quarter worth approximately $45,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Contineum Therapeutics during the second quarter worth approximately $76,000.

Contineum Therapeutics Stock Down 1.9%

Shares of CTNM stock opened at $12.16 on Thursday. The firm has a fifty day moving average of $13.04 and a 200-day moving average of $12.99. Contineum Therapeutics, Inc. has a 12-month low of $3.57 and a 12-month high of $16.33. The company has a market capitalization of $454.66 million, a price-to-earnings ratio of -6.24 and a beta of 0.89.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.16. On average, equities analysts expect that Contineum Therapeutics, Inc. will post -1.68 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CTNM shares. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Monday, April 20th. Morgan Stanley upped their target price on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Finally, Robert W. Baird increased their price objective on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Contineum Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.